

Ref: GLL/SE/2023-24/Sep

Date: 30/09/2023

To  
Corporate Relations Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001.  
Maharashtra State, India.

To  
Listing Manager  
The Ahmedabad Stock Exchange Limited  
A-2, Kamdhenu Complex,  
Opposite Sahajanand College,  
120 Feet Ring Rd, Panjara Pol, Ambawadi,  
Ahmedabad - 380 015

To  
The Secretary  
The Calcutta Stock Exchange Limited  
#7, Lyons Range, Murgighata,  
Dalhousie, Kolkata - 700 001

Dear Sir/Madam,

**Sub: Proceedings of the 38th electronic Annual General Meeting of the Company**

Pursuant to Reg.30 of SEBI (LODR) Regulations, 2015, we are pleased to provide hereunder the proceedings of 38th Annual General Meeting (AGM) of the Company held on Saturday, September 30, 2023 through video conferencing ('VC') / other audio visual means ('OA VM'). The meeting was held in compliance with Circulars issued by Ministry of Corporate Affairs (MCA) # 14 /2020 dated April 08, 2020, #02/2021 dated January 13, 2021, and Circular No.02/2022 dated May 05, 2022 and SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021 and Circular No. SEBI/HO/DDHS/P/CIR/2022/0063 dated May 13, 2022, issued by Securities and Exchange Board of India (SEBI) and other applicable provisions of the Companies Act, 2013 read with rules made thereunder.

The Meeting commenced at 12:30 Hrs and concluded at 12.40 Hrs. All the requisite Statutory Registers and other requisite documents were available electronically during the AGM for inspection by the members.

This intimation is also uploaded in the Company website: [www.gennexlab.com](http://www.gennexlab.com).

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

**For Gennex Laboratories Limited**

**Dinesh Kumar Kejriwal**  
Company Secretary & Compliance Officer



**Gennex Laboratories Limited**



**Brief Summary of proceedings of the 38th electronic Annual General Meeting of Gennex Laboratories Limited.**

The 38th electronic Annual General Meeting (eAGM) of the Members of Gennex Laboratories Limited ("the Company") was held on Saturday, September 30, 2023 at 12:30 Hrs (IST) through Video Conference ("VC")/ Other Audio Visual Means ("OAVM"). The meeting was held in compliance with the General Circular issued by the Ministry of Corporate Affairs ("MCA") and Securities and Exchange Board of India ("SEBI") and as per the applicable provisions of the Companies Act, 2013 and the Rules made thereunder.

**Directors in attendance**

S. No.	Name of the Director	Designation	Attended through VC/OAVM from
1.	Mr. Arihant Baid	Managing Director	Kolkata
2.	Mr. T M Gopalakrishnan	Whole-time Director	Hyderabad
3.	Mr. Y Ravinder Reddy	Independent Director/ Chairman of Audit Committee	Hyderabad
4.	Mr. Dr Avasarala Ranga Rao Pantulu	Non-Executive Director	Hyderabad

**In Attendance**

S. No.	Name of the Designated person	Designation	Attended through VC/OAVM from
1.	Mr. L P Baid	Chief Financial Officer	Hyderabad
2.	Mr. Dinesh Kumar Kejriwal	Company Secretary & Compliance Officer	Hyderabad
3.	Mrs. Ekta Goswami	Scrutinizer	Kolkata

Mr. Amudala Sreeramulu Nageswar Rao, Independent Director and Ms. Sadhana Bhansali, Independent/Women Director of the Company were unable to attend the meeting due to unavoidable reasons.

**Other Representatives**

**Quorum:**

A total of 43 Members attended the meeting through VC.

**Chairman:**

Mr Arihant Baid, Chairman, took the chair and commenced the proceedings of the meeting after ascertaining that the requisite quorum was present.

The meeting commenced at 12:30 p.m. (IST) and concluded at 12.40 (IST) (Including time allowed for e-voting at AGM).

Mr. Dinesh Kejriwal - Company Secretary, welcomed the Members and other attendees for the meeting. He informed that the Company had enabled the Members to participate in the 38th eAGM through the VC facility provided by the Company through NSDL. It was further informed that the Members were provided with the facility to exercise their right to vote by electronic means, through remote e-voting and e-voting at the AGM in accordance with the provisions of the

**Gennex Laboratories Limited**

Office : 'Akash Ganga' 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad-500073, T.S, India | Phone : +91-40-67334400 (30 Lines), Fax : +91-40-67334483  
 Factory : Sy. No. 133, IDA Bollaram, Jinnaram Mandal, Sangareddy Dist - 502 325. Telangana, India | Tel : +91-08458 279406, Telefax : +91-08458 279516

info@gennexlab.com, www.gennexlab.com ■ CIN : L24230TG1990PLC011168





Companies Act, 2013 and SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Members who have joined the meeting through VC and who had not cast their vote through remote e-voting, were provided the option to vote through e-voting facility made available at the AGM. The Company had appointed Mrs. Ekta Goswami, Practising Company Secretary, as Scrutinizer to supervise the e-voting process and to provide combined voting results of remote e-voting and e-voting at the AGM along with the Scrutinizers Report.

It was further informed that as the AGM was held through VC/OAVM, the facility for appointment of Proxies by the members was not applicable and hence, the proxy register was not available for inspection. The members were also briefed about the process for questions & answers and e-Voting.

Thereafter, the Chairman delivered his speech followed by the presentation. The 38th Annual report and the Notice of the Thirty Eighth Annual General Meeting and the Board's Report along with annexures which was already circulated through electronic mode to those members who were holding shares of the Company as on September 06, 2023, and whose email ID's are registered with the Company /Depositories. Resolutions were taken as read. All the resolutions were taken up by Mr. Arihant Baid,

The Chairman then commenced his speech and gave an overview of the operations and the financial performance of the Company during FY 2022-23 and also the impact of Covid-19 pandemic on Indian economy and also the challenges and opportunities for the Pharma Sector in India. Thereafter, Mr. Dinesh Kejriwal, Company Secretary invited speaker shareholders, who had done prior registrations, to speak and ask questions, if any

Clarifications were provided by the Chairman and Mr. T M Gopalakrishnan, Whole-time Director to the queries raised by the Members, immediately after the Question & Answers session.

The following items of business as set out in the Notice of the 38th eAGM, were transacted:

S.No.	Resolution	Type of Resolution
	<b>Ordinary Business:</b>	
1.	Adoption of financial statements: a) The audited Standalone Revenue Account, Profit and Loss Account and Receipts & Payments Account of the Company for the financial year ended March 31, 2023, and the Balance Sheet as at that date, together with the Reports of the Directors and Auditors thereon; and b) The audited Consolidated Revenue Account, Profit and Loss Account and Receipts & Payments Account of the Company for the financial year ended March 31, 2023 and the Balance Sheet as at that date, together with the report of the Auditors thereon.	Ordinary
2.	To appoint a Director in the place of Mr. Arihant Baid (DIN: 01171845) who retires by rotation being eligible offers himself for re-appointment as Director liable to retire by rotation.	Ordinary
3.	Appointment of M/s. R. Pugalia & Co. as Statutory Auditors of the Company.	Ordinary
	<b>Special Business:</b>	
4.	Ratification of Remuneration of Cost Auditors.	Ordinary

Mrs. Ekta Goswami, Company Secretary, appointed as Scrutinizer to Scrutinize the votes cast in this AGM & remote e-voting and submit a consolidated report thereon. The Consolidated Scrutinizer's report in prescribed format along with the details of the voting results (remote e-voting & e-voting at AGM) on all the resolutions as set out in the Notice of the AGM, pursuant to the regulation 4 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 will be submitted to the Stock exchange within prescribed timelines.





The Chairman authorised Mr. Dinesh Kejriwal, Company Secretary to receive the Scrutinizer's Report & related documents, declare the result and submit the same to the Stock Exchange.

These reports will also be uploaded in the Company website of the Company and on the website of BSE Limited.


Mr. Dinesh Kejriwal, Company Secretary, concluded his speech by placing on record his appreciation and gratitude for all the stakeholders for having reposed their trust and confidence in the Company, the voting lines kept open for 15 minutes for the members to vote.

Mr. Dinesh Kejriwal, Company Secretary, thereafter, the members that the meeting was concluded.

Thanking you,

Yours Truly,

**For Gennex Laboratories Limited**

  
**Dinesh Kumar Kejriwal**  
Company Secretary & Compliance Officer

